Asia’s Largest Web3 Event TOKEN2049 Singapore Announces Title Sponsors
7.6.2022 09:37:00 EEST | Business Wire | Press release
TOKEN2049, Asia’s premier crypto conference, has announced a number of high profile Title Sponsors for its much-anticipated Singapore debut. Taking place from 28-29 September 2022, this year’s event marks TOKEN2049’s first physical presence in Singapore, which will be held in conjunction with the Formula 1 Singapore Grand Prix 2022, ahead of the race weekend.
As the flagship event of Asia Crypto Week, the conference is set to see over 3,000 attendees as they gather to learn from prominent thought leaders and innovators across the crypto industry, including the CEOs and founders of some of the world’s largest crypto-related projects. Over 130 sponsors and exhibitors have already confirmed their participation with numbers steadily rising as anticipation builds ahead of September.
“TOKEN2049 is shaping up well in bringing together the brightest minds of our ecosystem in exploring pathways of innovation and collaboration. As one of the leading enablers dedicated to unlocking the full potential of digital assets, we look forward to the dialogue and conversations at this gathering,” said Cynthia Wu, Founding Partner at Matrixport.
With this year’s agenda spanning institutional investment trends to the rise of the metaverse and Web3, the diversity of this year’s title sponsors for TOKEN2049 Singapore is a testament to a flourishing industry ecosystem. This includes Singapore-based crypto unicorn and digital assets financial services platform Matrixport; leading cryptocurrency exchange app and Formula 1 global partner Crypto.com; global leader in digital assets products and infrastructure Amber Group; revolutionary social currency $WHALE which is backed by one of the largest and most valuable NFT collections in the world; community-governed DeFi platform MantraDAO; and collaborative Web3 credential infrastructure Project Galaxy.
Celebrating the upcoming event, Raphael Strauch, Founder of TOKEN2049 said: “Within the past few months, the crypto ecosystem has seen a whirlwind of change and growth, and it’s only befitting that we’re gathering in Singapore — one of the region’s leading innovation hubs — to celebrate how far we’ve come.”
Alongside its impressive speaker line-up including Pantera Capital CEO Dan Morehead, Ava Labs CEO Emin Gün Sirer, Three Arrows Capital CIO and CEO Su Zhu. Additional title sponsors at the event include enterprise-grade crypto infrastructure company Fireblocks; cryptocurrency exchange and derivative trading platform Bitmex; the EOS Network Foundation which is building a coordinated future for the EOS Network through decentralization and community; decentralised and open-source platform Syscoin; Asia’s leading institutional digital asset custodian Hextrust; global online identity verification platform Trulioo; the blockchain platform TRON and the first official Ethereum Virtual Machine based on the EOS network Trust EVM.
“From our decorated bench of Title Sponsors to our speaker line-up, we’re thrilled to see continued support from so many of the industry’s leading organizations and are looking forward to spotlighting some of the most exciting, emerging voices across the ecosystem. We’ve seen tremendous interest from potential speakers and sponsors alike, and are thrilled to deliver a top-notch conference experience for all. To that end, we are very excited to be hosting a large closing party CÉ LA VI Singapore, on the rooftop deck of the Marina Bay Sands, overlooking the F1 Grand Prix track, with several notable European DJs flying in to grace the event,” continued Strauch.
For more information and continued updates on TOKEN2049 Singapore, please visit: https://www.asia.token2049.com/
Raphael Strauch, Founder of TOKEN2049 is available for interview.
About TOKEN2049:
TOKEN2049 is a premier Web3 event, organised annually in Singapore and London, where decision-makers in the global crypto ecosystem connect to exchange ideas, network, and shape the industry. TOKEN2049 is a global meeting place for entrepreneurs, institutions, industry insiders, investors, and those with a strong interest in the crypto and blockchain industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606006051/en/
Contact information
Media:
Melissa Esguerra
Senior Consultant
Wachsman
melissa.esguerra@wachsman.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Codethink Opens Early Access to IEC 61508 Mapping for the Eclipse Trustable Software Framework11.3.2026 09:07:00 EET | Press release
EMBEDDED WORLD--Codethink today opened early access to its mapping between the Eclipse Trustable Software Framework (TSF) and IEC 61508, the international standard governing the functional safety of electrical and electronic systems. The mapping establishes a transparent relationship between the engineering principles of the Trustable Software Framework and the objectives defined in IEC 61508. By making this work available as an early preview, Codethink is inviting organisations interested in applying open source approaches to functional safety to review and begin working with the mapping while the work continues to mature. IEC 61508 forms the foundation of many domain-specific safety standards, including ISO 26262 for automotive systems. The early access reflects Codethink’s long-standing commitment to open development of software engineering methods. “This preview release reflects our belief that trust in software must be engineered in the open," said Paul Sherwood, Codethink’s Chair
FERM FOOD Acquires Orkla’s Former Site and Scales Up: Up to 20,000 Tonnes of Fermented Ingredients Per Year11.3.2026 08:00:00 EET | Press release
Danish ingredient producer FERM FOOD is acquiring Orkla’s former manufacturing site in Skovlund, Denmark, effective 1 April 2026. The acquisition provides new production facilities to expand the output of fermented plant-based ingredients for the food industry — driven by export demand that has emerged faster than expected. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310904877/en/ Jens Legarth (CEO), Rikke Matthiesen (CSO), and Torbjørn Tyndkjær-Thomsen (Food & Process Developer) at FERM FOOD’s new production facilities. “We have outgrown our current facilities. With the Skovlund site, we can supply many more food manufacturers in Denmark and abroad. Global interest has developed faster than we expected — and that is why we are scaling up now,” says Jens Legarth, CEO of FERM FOOD. Once fully ramped up, the new fermentation facility is expected to reach an annual capacity of up to 20,000 tonnes, depending on product mix
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for future use in connection with Galderma's employe
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 08:00:00 EET | Press release
As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/en/ SkyDefender © Thales Thales SkyDefender provides full protection against all types of air threats, from a few kilometres to several thousands of kilometres: Short-range: for protection of forces, vital assets and sensitive sites: ForceShield creates a real protection bubble against lower layer and surface threats at very short- and short-range, such as drones. Medium-range: for protection at theatre-level defence: SAMP-T NG by eurosam1 with up to 150 km engagement range, including Thales’ powerful Ground Fire radar with 350 km range and 360°/90° coverage against medium-range defence. Long-range: for protection against long-range threats with early-warning capabilities: a unique capacity
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan11.3.2026 08:00:00 EET | Press release
Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rights to develop and commercialize corticorelin for the treatment of peritumoral brain edema (PTBE) in Japan. PTBE is a tumor-associated condition for which no approved targeted therapies currently exist. Neupharma will finance and conduct a pivotal clinical trial in Japan to support filing for approval in Japan. Curatis will receive upfront and milestone payments for the achievement of regulatory and commercial targets totaling up to CHF 83.5 million, as well as royalties on future sales in Japan of up to 20%. The agreement stipulates that corticorelin is planned to be introduced in Japan initially for children and adolescents. A meeting with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom